134. Cancer Lett. 2018 Sep 28;432:103-111. doi: 10.1016/j.canlet.2018.06.001. Epub2018 Jun 5.Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ ina triple-negative breast cancer model in mice.Sauvage F(1), Fattal E(1), Al-Shaer W(1), Denis S(1), Brotin E(2), DenoyelleC(2), Blanc-Fournier C(3), Toussaint B(4), Messaoudi S(5), Alami M(5), BarrattG(1), Vergnaud-Gauduchon J(6).Author information: (1)Institut Galien Paris-Sud, CNRS, UMR 8612, LabEx LERMIT, UniversitéParis-Saclay, Faculté de Pharmacie, 5 Rue J.-B. Clément, Châtenay-Malabry,F-92296, France.(2)Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE « Interdisciplinary ResearchUnit for Cancer Prevention and Treatment », Biology and Innovative Therapeuticsfor Ovarian Cancers Group (BioTICLA), ImpedanCELL core facility, SF 4206 ICORE,Centre de Lutte Contre le Cancer F. Baclesse, 3 Avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 Avenuedu Général Harris, 14076, Caen, France.(3)Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE « Interdisciplinary ResearchUnit for Cancer Prevention and Treatment », Biology and Innovative Therapeuticsfor Ovarian Cancers Group (BioTICLA), ImpedanCELL core facility, SF 4206 ICORE,Centre de Lutte Contre le Cancer F. Baclesse, 3 Avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 Avenuedu Général Harris, 14076, Caen, France; Department of BioPathology, Centre deLutte Contre le Cancer F. Baclesse, 3 Avenue du Général Harris, 14076, Caen,France.(4)Institut Galien Paris-Sud, CNRS, UMR 8612, LabEx LERMIT, UniversitéParis-Saclay, Faculté de Pharmacie, 5 Rue J.-B. Clément, Châtenay-Malabry,F-92296, France; Laboratoire de Développement Analytique, Agence Générale desEquipements et Produits de Santé, AP-HP, Paris, France.(5)University Paris-Sud, CNRS, BioCIS-UMR 8076, Laboratoire de ChimieThérapeutique, Equipe Labellisée Ligue Contre Le Cancer, LabEx LERMIT, UniversitéParis-Saclay, Faculté de Pharmacie, 5 Rue J.-B. Clément, Châtenay-Malabry,F-92296, France.(6)Institut Galien Paris-Sud, CNRS, UMR 8612, LabEx LERMIT, UniversitéParis-Saclay, Faculté de Pharmacie, 5 Rue J.-B. Clément, Châtenay-Malabry,F-92296, France. Electronic address: Juliette.vergnaud@u-psud.fr.In this study, we investigated the anticancer efficacy of pegylated liposomescontaining 6BrCaQ, an hsp90 inhibitor derived from novobiocin. 6BrCaQ has beenpreviously identified as the most potent compound in a series of quinoleicnovobiocin analogs but is poorly water-soluble. We investigated, for the firsttime, the anti-proliferative effects of this drug in vivo in an orthotopic breastcancer model (MDA-MB-231 luc) using pegylated liposomes to allow itsadministration. Hsp90, hsp70 and hsp27 protein and mRNA expressions were notstrongly affected after treatment meaning it did not induce a heat shock responseoften associated with resistance and poor prognosis. Liposomal delivery of 6BrCaQretarded tumor growth at a low dose (1 mg/kg, injected once a week for 4 weeks). Histological analysis of tumors revealed necrosis and a lower proportion ofproliferative cells in treated mice indicating that this drug has potential forbreast cancer therapy when encapsulated in liposomes.Copyright © 2018 Elsevier B.V. All rights reserved.DOI: 10.1016/j.canlet.2018.06.001 PMID: 29883750 